Background Sacubitril/valsartan (S/V) demonstrated significant effects in improving left
ventricular performance and remodeling in patients with heart failure with reduced ejection …

Background: Heart failure (HF) patients commonly experience obstructive sleep apnea
(OSA), which may worsen their condition. We reviewed a diverse range of studies to …

Background: right ventricle-pulmonary artery (RV-PA) coupling assessed by measuring the
tricuspid anular plane systolic excursion (TAPSE)/pulmonary artery systolic pressure (PASP) …

Background To assess the impact of sacubitril-valsartan on apneic burden in patients with
heart failure with reduced ejection fraction (HFrEF), 51 stable HFrEF patients planned for …

Background Compared to angiotensin inhibition, angiotensin-neprilysin “blockade”
improves mortality and reduces hospitalizations in patients with heart failure (HF) with …

Background. Heart failure with reduced ejection fraction (HFrEF) is a clinical condition
frequently diagnosed in clinical practice. In patients affected by HFrEF, sleep apnea (SA) …

Aim Sacubitril valsartan (SV) has revolutionized disease history in patients with heart failure
and reduced ejection fraction (HFrEF). Our study assessed SV impact on clinical and …

The sacubitril/valsartan combination is an important agent used in the treatment of heart
failure with reduced ejection fraction (HFrEF). Pulmonary artery stiffness (PAS) is an index …

Background The effects of sacubitril/valsartan (sac/val) on metabolic parameters and insulin
resistance (IR) in non-obese/prediabetic patients have not been previously described. Aim …

To observe the effects and safety of Sacubitril/Valsartan (SV) on heart function and blood
pressure in maintenance hemodialysis (MHD) patients with chronic heart failure (CHF). The …